GlassScriptPhysician profile
Michael H Sumko
NPI 1609987270
$1,084.80
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $56.29 · 2020: $230 · 2021: $360 · 2022: $237 · 2023: $139 · 2024: $61.82.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $201.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $201.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Therapeutics, INC. | $398.87 | 2019-2021 | |
| Stryker Corporation | $156.94 | 2020-2021 | |
| Abbott Laboratories | $124.97 | 2023-2024 | Proclaim |
| Zimmer Biomet Holdings, INC. | $107.14 | 2021-2022 | |
| Anika Therapeutics, INC. | $91.31 | 2022-2024 | Wristmotion, Total Anika, Integrity |
| Smith+Nephew, INC. | $24.81 | 2019 | |
| Endo Pharmaceuticals INC. | $23.62 | 2022 | |
| Nalu Medical, INC. | $18.65 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.63 | 2022 | |
| Cranial Technologies, INC | $16.40 | 2021 | |
| Shield Therapeutics INC | $15.89 | 2024 | |
| Ultragenyx Pharmaceutical INC. | $14.61 | 2022 | |
| Lilly USA, LLC | $14.10 | 2022 | |
| Lucid Diagnostics INC. | $13.18 | 2022 | |
| Sanofi-Aventis U.S. LLC | $12.82 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dynavax Technologies Corporation | $12.65 | 2022 | |
| Depuy Synthes Sales INC. | $11.76 | 2019 | |
| Organon LLC | $8.45 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Sumko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.